Antibiotics for bronchiolitis in children (Review) by Spurling, Geoff K.P. et al.
Antibiotics for bronchiolitis in children (Review)
Spurling GKP, Doust J, Del Mar CB, Eriksson L
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2011, Issue 6
http://www.thecochranelibrary.com
Antibiotics for bronchiolitis in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
8DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Length of symptoms (not specified), Outcome 1 Duration of symptoms. . . . . . . 19
Analysis 1.2. Comparison 1 Length of symptoms (not specified), Outcome 2 Duration of fever (days). . . . . . 19
Analysis 2.1. Comparison 2 Death, Outcome 1 Deaths. . . . . . . . . . . . . . . . . . . . . . 20
Analysis 3.1. Comparison 3 Length of hospital stay, Outcome 1 Length of hospital stay. . . . . . . . . . . 21
Analysis 4.1. Comparison 4 Use of alternative therapy, Outcome 1 Use of alternative therapy. . . . . . . . . 22
Analysis 4.2. Comparison 4 Use of alternative therapy, Outcome 2 Duration of bronchodilator use. . . . . . . 22
Analysis 4.3. Comparison 4 Use of alternative therapy, Outcome 3 Days of supplementary oxygen. . . . . . . 23
Analysis 4.4. Comparison 4 Use of alternative therapy, Outcome 4 Days of tube feeding. . . . . . . . . . . 24
Analysis 5.1. Comparison 5 PICU admission, Outcome 1 PICU admission. . . . . . . . . . . . . . . 24
Analysis 6.1. Comparison 6 Re-admission, Outcome 1 Re-admission. . . . . . . . . . . . . . . . . . 25
Analysis 7.1. Comparison 7 Symptoms, Outcome 1 Wheeze. . . . . . . . . . . . . . . . . . . . . 25
Analysis 7.2. Comparison 7 Symptoms, Outcome 2 Shortness of breath. . . . . . . . . . . . . . . . . 26
Analysis 7.3. Comparison 7 Symptoms, Outcome 3 Oxygen saturation (< 96%). . . . . . . . . . . . . . 27
Analysis 7.4. Comparison 7 Symptoms, Outcome 4 Not smiling socially. . . . . . . . . . . . . . . . 27
Analysis 7.5. Comparison 7 Symptoms, Outcome 5 Feeding difficulties. . . . . . . . . . . . . . . . . 28
Analysis 7.6. Comparison 7 Symptoms, Outcome 6 Fever. . . . . . . . . . . . . . . . . . . . . 28
Analysis 7.7. Comparison 7 Symptoms, Outcome 7 Cough. . . . . . . . . . . . . . . . . . . . . 29
29ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAntibiotics for bronchiolitis in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antibiotics for bronchiolitis in children
Geoffrey KP Spurling1, Jenny Doust2 , Chris B Del Mar3, Lars Eriksson4
1Discipline of General Practice, Level 2, Edith Cavell Building, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia.
2Centre for Research in Evidence Based Practice, Bond University, Gold Coast, Australia. 3Faculty of Health Sciences and Medicine,
Bond University, Gold Coast, Australia. 4Herston Health Sciences Library, University of Queensland Library, Brisbane, Australia
Contact address: Geoffrey KP Spurling, Discipline of General Practice, Level 2, Edith Cavell Building, University of Queensland, Royal
Brisbane Hospital, Brisbane, Queensland, 4029, Australia. g.spurling@uq.edu.au. geoffspurling@optusnet.com.au.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: Edited (no change to conclusions), published in Issue 11, 2011.
Review content assessed as up-to-date: 9 December 2010.
Citation: Spurling GKP, Doust J, Del Mar CB, Eriksson L. Antibiotics for bronchiolitis in children. Cochrane Database of Systematic
Reviews 2011, Issue 6. Art. No.: CD005189. DOI: 10.1002/14651858.CD005189.pub3.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Bronchiolitis is a serious, potentially life-threatening respiratory illness commonly affecting babies. It is often caused by respiratory
syncytial virus (RSV). Antibiotics are not recommended for bronchiolitis unless there is concern about complications such as secondary
bacterial pneumonia or respiratory failure. Nevertheless, they are used at rates of 34% to 99% in uncomplicated cases.
Objectives
To evaluate the effectiveness of antibiotics for bronchiolitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2010, issue 4), which includes the Cochrane Acute
Respiratory Infection Group’s Specialised Register, and the Database of Abstracts of Reviews of Effects, MEDLINE (January 1966 to
November 2010), EMBASE (1990 to December 2010) and Current Contents (2001 to December 2010).
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics to placebo in children under two years diagnosed with bronchiolitis, using
clinical criteria (including respiratory distress preceded by coryzal symptoms with or without fever). Primary clinical outcomes included
time to resolution of signs or symptoms (pulmonary markers included respiratory distress, wheeze, crepitations, oxygen saturation and
fever). Secondary outcomes included hospital admissions, length of hospital stay, re-admissions, complications or adverse events and
radiological findings.
Data collection and analysis
Two review authors independently analysed the search results.
Main results
Five studies (543 participants) met our inclusion criteria. One study randomised 52 children to either ampicillin or placebo and
found no significant difference between the two groups for length of illness. A small study (21 children) with higher risk of potential
bias randomised children with proven RSV infection to clarithromycin or placebo and found clarithromycin may reduce hospital re-
admission (8% antibiotics versus 44% placebo; Fishers exact; P = 0.081). The two studies (267 children) providing adequate data for
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length of hospital stay showed no difference between antibiotics and control (pooled mean difference 0.34; 95% CI -0.71 to 1.38).
Two studies randomised children to intravenous ampicillin, oral erythromycin and control and found no difference for most symptom
measures. None of the trials reported deaths.
Authors’ conclusions
This review found minimal evidence to support the use of antibiotics for bronchiolitis. Research to identify a possible small subgroup
of patients who have complications from bronchiolitis such as respiratory failure and who may benefit from antibiotics is justified.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for bronchiolitis in babies
Bronchiolitis is a serious respiratory illness that often affects young babies. It is most commonly caused by respiratory syncytial virus
(RSV) and is the most common reason for hospitalisation in babies under the age of six months. Babies usually present with runny nose,
cough, shortness of breath and signs of respiratory distress which can become life-threatening. Despite its viral cause, antibiotics are
prescribed in 34% to 99% of cases. Prescribers may be expecting benefits from anti-inflammatory effects attributed to some antibiotics
or be concerned about secondary bacterial infection, particularly in children who are very unwell and require intensive care admission.
This systematic review found five trials (543 participants) comparing antibiotics with placebo or no antibiotics. Two of these also
compared intravenous and oral antibiotics. Two trials showed that antibiotics are no better than placebo at reducing the length of illness
of bronchiolitis and hospitalisation. Two more recent studies comparing antibiotics with no antibiotics found no improvement in the
length of illness or hospitalisation. One smaller, poorer quality trial found benefit for antibiotics over placebo for some outcomes. Only
one of the five included trials had a low risk of bias. Antibiotics may be justified in children who are very unwell and requiring intensive
care admission. Antibiotics need to be used cautiously owing to the potential for side effects, cost to the patient and the community
and increasing bacterial resistance to antibiotics.
B A C K G R O U N D
Description of the condition
Bronchiolitis is a serious, potentially life-threatening respiratory
illness that often affects young babies. It occurs most frequently
in the first year of life and is the commonest cause of hospital
admissions in infants under six months of age (Wohl 1978). The
most commonly identified pathogen is respiratory syncytial virus
(RSV).Other viruses such as humanmeta-pneumovirus (HMPV),
influenza, parainfluenza, adenovirus and rhinovirus have also been
implicated (Williams 2004). Other less common pathogens in-
clude Mycoplasma pneumoniae (M. pneumoniae) which can oc-
cur in sporadic outbreaks (Glezen 1971; Rose 1987). The diag-
nosis is most often made on clinical grounds, which usually in-
cludes tachypnoea andwheezing in children under two years of age
(Bordley 2004). Immunofluorescence and culture of the nasopha-
ryngeal aspirate may be used to determine the causative organ-
ism and may reduce antibiotic use (Christakis 2005). A chest X-
ray may show hyperinflation and patchy atelectasis (Smyth 2006).
There are few effective therapies, including antiviral therapies
(Smyth 2006).
Description of the intervention
Antibiotics are not recommended unless there is concern about
complications such as secondary bacterial pneumonia (Fitzgerald
2004; Lozano 2002). This is based on evidence suggesting a low
risk of bacteraemia (0.2%) in children with bronchiolitis and fever
- a lower risk than for children with a fever without a recognisable
illness, where the rate ranges from 2% to 7% (Greenes 1999).
Antibiotic use comes with significant harms including common
adverse reactions (rash, abdominal pain, diarrhoea and vomiting),
cost and community bacterial resistance (Brook 1998).
Infants with severe bronchiolitis requiring mechanical ventilation
have been shown to have high rates of bacterial co-infection. Bac-
terial co-infection rates vary from 21% (Thorburn 2006) to 26%
(Kneyber 2005) measured in both from endotracheal aspirates.
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Consistent with these results, Kneyber 2005 reported antibiotic
use at 95% in infants with bronchiolitis in intensive care.
Antibiotics are commonly used in hospitalised infants even in
children who are not ventilated, at rates of 34% (Vogel 2003),
45% (Christakis 2005; Thorburn 2006) and 99% (Kabir 2003).
In one outpatient study antibiotics were used in 53% of children
with bronchiolitis. (Halna 2005)
How the intervention might work
Antibiotics may be useful in cases of illness where superinfection
with bacteria occurs, although it is unlikely that antibiotics will
be effective for a condition that only has a viral cause. However,
some antibiotics may have anti-inflammatory effects which may
improve symptoms.
Why it is important to do this review
The use of antibiotics for uncomplicated bronchiolitis is common
yet is not justified by our understanding of bronchiolitis as a viral
illness. The discord between clinical practice and the pathophysi-
ological understanding of bronchiolitis as a viral illness will benefit
from the empirical evidence offered by this systematic review.
O B J E C T I V E S
The objective of this review is to evaluate clinical outcomes result-
ing from the use of antibiotics for bronchiolitis in children com-
pared to placebo or other interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Single or double-blind randomised controlled trials (RCTs) com-
paring antibiotics to placebo or control to treat bronchiolitis.
Types of participants
Children under the age of two years diagnosed with bronchioli-
tis using clinical criteria, such as respiratory distress preceded by
coryzal symptoms, with or without fever.
Types of interventions
Oral, intravenous, intramuscular or inhaled antibiotics versus
placebo.
Types of outcome measures
Primary outcomes
Time for the resolution of symptoms/signs:
1. pulmonary markers;
2. respiratory distress;
3. wheeze;
4. crepitations;
5. oxygen saturation; and
6. fever.
Secondary outcomes
1. Hospital admissions.
2. Time to discharge from hospital.
3. Re-admissions.
4. Complications/adverse events developed.
5. Radiological findings.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: The Cochrane Li-
brary, CochraneCentral Register of ControlledTrials (CENTRAL
2010, issue 4), which includes theCochrane Acute Respiratory In-
fection Group’s Specialised Register, and theDatabase of Abstracts
of Reviews of Effects (DARE 2010, Issue 4), MEDLINE (January
1966 to NovemberWeek 3, 2010), EMBASE (1990 to December
2010) and Current Contents (2001 to December 2010).
We used multiple strategies to identify as many trials as possible
that met the inclusion criteria, regardless of language or publica-
tion status. We used the following search terms to search MED-
LINE andCENTRAL.We combined theMEDLINE search strat-
egy with the Cochrane Highly Sensitive Search Strategy for identi-
fying randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision):Ovid format (Lefebvre 2011).
Wemodified these terms to search EMBASE (see Appendix 1) and
Current Contents (see Appendix 2).
MEDLINE (OVID)
1 exp Bronchiolitis/
2 bronchiolit$.mp.
3 exp Respiratory Syncytial Viruses/
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4 exp Respiratory Syncytial Virus Infections/
5 (respiratory syncytial virus$ or RSV$).mp.
6 1 or 2 or 3 or 4 or 5
7 exp Anti-Bacterial Agents/
8 antibiotic$.mp.
9 exp Macrolides/
10 (macrolide$ or azithromycin or clarithromycin or ery-
thromycin or roxithromycin or spiramycin).mp.
11 exp Cephalosporins/
12 (cephalosporin$ or cephalexin or cephaclor or cefaclor or ce-
fepime or cefotaxime or cephamycin$ or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftri-
axone or cephamandole or cephazolin).mp.
13 exp Penicillins/
14 (penicillin$ or amoxicillin or amoxycillin or ampicillin or
benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or
piperacillin or ticarcillin or sulbactam).mp.
15 exp Fluoroquinolones/
16 (fluoroquinolone$ or ciprofloxacin or enoxacin or norfloxacin
or ofloxacin or pefloxacin or fleroxacin or levofloxacin or moxi-
floxacin).mp.
17 exp Tetracycline/
18 (tetracycline$ or doxycycline or methacycline or minocy-
cline).mp.
19 (amikacin or gentamicin or neomycin or netilmicin).mp.
20 (clindamycin or lincomycin).mp.
21 (chloramphenicol or amantadine or cotrimoxazole or trimetho-
prim).mp.
22 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or
18 or 19 or 20 or 21
23 exp Child/
24 (children or infant$ or pediatric or pediatric).mp.
25 23 or 24
26 6 and 22 and 25
Searching other resources
We considered all languages. We handsearched the references of all
identified studies. One review author (GS) and an expert librarian
(LE) carried out the search. We contacted experts in the field
looking for unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (GS, CDM) independently scanned abstracts
from the initial search results to identify trials that loosely met the
inclusion criteria. Two review authors (CDM, JD) independently
reviewed the full-text articles and applied the inclusion criteria.
Data extraction and management
Two review authors (CDM, JD) independently extracted data
from included studies using data extraction forms which included
type of intervention, adverse events, continuous and dichotomous
outcomes. We also noted the setting (hospital or primary care),
study population and any additional interventions or tests.
Assessment of risk of bias in included studies
We rated the quality of each eligible RCT according to the ’Risk
of bias’ tool available in RevMan 5.1 (RevMan 5.1) and criteria set
out in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). We assessed methodological quality under
the headings of allocation, blinding, incomplete outcome data,
selective reporting and other potential sources of bias. Two review
authors (JD, CDM) independently assessed the methodological
quality of the new included trials for this review update. We re-
solved any disagreement between the review authors by discussion.
Measures of treatment effect
We analysed data using RevMan 5.1 (RevMan 5.1). We expressed
continuous data comparisons using mean differences (MD) where
there was one study or standardised mean difference (SMD)where
more than one study used different measurement scales. We ex-
pressed dichotomous data using odds ratios (OR).We pooled data
into clinical outcomes where multiple trial results for the same
clinical presentation existed and heterogeneity did not preclude
pooling of results
Unit of analysis issues
The unit of analysis for each outcome was the individual research
participant.
Dealing with missing data
Intention-to-treat (ITT) analyses were conducted in Kneyber
2008 (no drop outs) and Kabir 2009 (10% drop outs, 32/327). In
the other three included studies it is not clear if ITT analyses were
carried out. In Mazumder 2009, 17.5% of participants dropped
out (22/126), while Field 1966 and Tahan 2007 had small num-
bers of drop outs.
Assessment of heterogeneity
Wewere only able to combine data for deaths and length of hospital
stay. Given there were no deaths we cannot assess heterogeneity
for that outcome. The two studies providing sufficient data to
compare length of hospital stay gave heterogenous results.
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Assessment of reporting biases
There was no evidence of publication bias nor reporting bias.
Data synthesis
We undertook meta-analysis for outcomes where there were suffi-
cient comparable data. Only two outcomes fitted this bill: deaths
and length of hospital stay.We were not able to combine symptom
measures owing to a lack of comparability of outcome measures or
the timing of measure was irreconcilably different. We undertook
narrative synthesis of the majority of results.
Subgroup analysis and investigation of heterogeneity
Not applicable.
Sensitivity analysis
Not applicable.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Initial database searching revealed the following results: 173 arti-
cles in MEDLINE, 102 articles in EMBASE, 23 articles in CEN-
TRAL and two articles inDARE.Of these 300 articles, we rejected
297 on the basis of title and abstract alone leaving three studies. In
this 2011 update, an additional 259 studies were identified, with
35 duplicates and 220 rejected on title and abstract alone with
four studies remaining. Of the seven studies identified from initial
and updated searches, two were excluded: one because it did not
involve clinical criteria for inclusion (Friis 1984) and one because
it did not involve an antibiotic (Boogaard 2007). Five studies did
meet inclusion criteria (Field 1966; Kabir 2009; Kneyber 2008;
Mazumder 2009; Tahan 2007).
Included studies
Field 1966, Tahan 2007, Kneyber 2008, Mazumder 2009 and
Kabir 2009 met the inclusion criteria randomising children to an-
tibiotics or control group. All study participants were children un-
der two years of age except for Tahan 2007 which only included
children under seven months of age. Two studies were conducted
in low-income countries (Kabir 2009; Mazumder 2009), both in
Bangladesh. These two studies compared oral erythromycin with
intravenous ampicillin and control. One study was conducted in
an upper-middle income country (Tahan 2007) (Turkey) and this
study compared clarithromycin with placebo. Kneyber 2008, con-
ducted in a high-income country, compared azithromycin with
placebo. Field 1966, also conducted in a high-income country,
compared oral ampicillin with placebo. All studies included par-
ticipants who were hospitalised and only one study recruited from
an outpatients department (Mazumder 2009).
Excluded studies
Boogaard 2007 did not study antibiotics for bronchiolitis. One
study was excluded (Friis 1984) because it dealt with both pneu-
monia and bronchiolitis using crepitations and radiography as cri-
teria for patient selection. The study did perform a subgroup anal-
ysis of the two groups (antibiotics and placebo) based on virolog-
ical diagnosis and these results are discussed.
Risk of bias in included studies
Risk of bias is summarised in Figure 1 and Figure 2.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Sequence generation was adequately described by Kneyber 2008
and Kabir 2009. Field 1966 probably also used an adequate ran-
domisation procedure. The randomisation process for Tahan 2007
is not adequately described and it was not adequately described in
Mazumder 2009. Only one of the five included studies adequately
described allocation concealment (Kneyber 2008).
Blinding
Three studies described adequate blinding of participants (all in-
fants), their parents and the investigators. Two did not discuss
blinding (Kabir 2009; Mazumder 2009). None of the studies de-
scribed blinding of the outcome assessor.
Incomplete outcome data
In the Mazumder 2009 trial, 22 participants (out of 124) were
excluded because they did not attend regular follow up (18) or
were persistently unwell. In the Kabir 2009 trial, 17 children were
referred to tertiary care where there was access to paediatric inten-
sive care and for 15 children their parents withdrew or they left
their respective hospitals. In Tahan 2007, nine participants were
excluded because they took corticosteroids. There were only 15
participants in each group and six were excluded from the placebo
group for taking corticosteroids and three from the clarithromycin
group. In Field 1966, eight patients were excluded from the study
owing to symptom severity (three from the ampicillin group and
five from the placebo group) with an extra two participants (one
from each group) lost to follow up at the end of the trial. There
were no drop outs from the Kneyber 2008 trial.
Selective reporting
There are no concerns about selective reporting.
Other potential sources of bias
No other concerns were identified.
Effects of interventions
Oral ampicillin versus placebo
Field 1966 randomised infants with the clinical presentation of
bronchiolitis to either placebo (24 patients) or ampicillin (28 pa-
tients). The main outcome measure was length of illness. This was
found to be 9.54 days in the group receiving ampicillin and 9.7
days in the group receiving placebo. This was not a significant dif-
ference as calculated by the study authors. There were insufficient
data provided for us to independently confirm this. There were
no deaths in either group.
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One excluded study (Friis 1984) analysed separately a subgroup
of children in their trial who tested positive for RSV. This trial
randomised 150 children who had either fine crepitating rales or
pulmonary consolidation on chest radiograph to either antibiotics
(ampicillin) or no antibiotics. While this trial did not start by
selecting children with a clinical presentation of bronchiolitis, the
results of the subgroup analysis are relevant. In children who were
RSV-positive, there was no significant difference found between
the antibiotic and no antibiotic groups for the outcomes of fever,
pulmonary symptoms, duration of hospital stay, otitis media or
chest radiograph findings.
Oral macrolide antibiotic versus placebo
Tahan 2007 randomised infants younger than seven months ad-
mitted to a department of paediatrics in Turkey to clarithromycin
for three weeks (15) or placebo (15) if they were found to be
positive for an RSV immunofluorescent test. Nine participants
were excluded owing to corticosteroid use leaving 12 in the clar-
ithromycin group and nine in the placebo group. Median hospi-
tal stay on clarithromycin was 2.13 days (interquartile range: 2
to 2.83) compared to 3.67 days (3 to 4.17). One participant was
readmitted in the clarithromycin group (8.3%) and four in the
placebo group (44%). Duration of beta-agonist use in the clar-
ithromycin group was five days (interquartile range: 5 to 7), for
placebo seven days (5 to 7). Duration of oxygen use in the clar-
ithromycin group was 31 hours (interquartile range: 28 to 42), for
placebo 72 hours (52 to 80). Duration of intravenous fluids for
the clarithromycin group was 26 hours (interquartile range: 22 to
36) and for placebo 56 hours (46 to 66).
Kneyber 2008 randomised infants younger than 24 months with
clinically-suspected viral bronchiolitis who were admitted to hos-
pital in theNetherlands to azithromycin (32 children) and placebo
(39 children). The primary outcome was length of hospital ad-
mission, which was 5.5 days (standard deviation (SD) 2.55) in
the azithromycin group and 5.82 days (SD 2.0), resulting in a
mean difference of -0.32 (95% confidence interval (CI) -1.40 to
0.76). Beta-agonists were used by 17 participants (mean duration:
2.8 days +/- 0.6 standard error (SE)) in the azithromycin group
and 23 participants (three days +/- 0.4 SE) in the placebo group.
Oxygen was used by 20 participants in the azithromycin group
(mean duration: 3.8 days +/- 0.4 SE) and 31 participants in the
placebo group (mean duration 3.4 days +/- 0.3). Other outcomes
are tabled (Table 1).
Oral macrolide antibiotic (erythromycin) versus
parenteral ampicillin versus control
Mazumder 2009 randomised infants younger than 24 months
(and older than one month) with clinically suspected bronchioli-
tis to intravenous ampicillin (29 children), oral erythromycin (32
children) and no antibiotics (43 children). Symptoms (wheeze,
shortness of breath, oxygen saturation less than 96%, lack of social
smile and feeding difficulties) were measured on days one, three
and five. There were significantly fewer children with wheeze in
the oral erythromycin group on day three but significantly fewer
children with wheeze in the control group on day five. None of the
other symptom measures differed significantly between the three
groups. Full results as reported by this study for the three groups
are tabled with Chi2 test results and significance levels (Table 2).
The two antibiotic arms of this trial were also combined and com-
pared with control. For most comparisons there was no significant
difference between antibiotics and control. For the outcome of
wheeze on day 3, significantly fewer children had wheeze in the
antibiotics arm (OR 0.27; 95% CI 0.12 to 0.62) (Analysis 7.1).
However, on day five significantly more children in the antibiotics
arm had wheeze compared with control (OR 5.55; 95% CI 1.18
to 26.05) (Analysis 7.1).
Kabir 2009 randomised infants younger than24monthswith clin-
ical signs of bronchiolitis (hospitalised with runny nose, cough,
breathing difficulty, chest indrawing and rhonchi on ausculta-
tion). Symptom resolution was measured as rapid (less than four
days) or gradual (more than four days). None of the symptom
measures differed significantly between parenteral ampicillin, oral
erythromycin and control (Table 3). Length of hospital stay did
not differ significantly between parenteral ampicillin and oral ery-
thromycin and control (Analysis 3.1).
Meta-analysis
There were no deaths in any arms of any of the five included trials.
For the outcome of length of hospital stay, the oral erythromycin
arm has been used from Kabir 2009 to provide a comparison with
the azithromycin arm of Kneyber 2008. There was no significant
difference (MD 0.34; 95% CI -0.71 to 1.38). The two study
results are heterogenous. Unfortunately incomplete data from
Tahan 2007 precludes comparison with this study.
While Kabir 2009 and Mazumder 2009 have the same interven-
tion arms they either measured symptoms at markedly different
times (for example, fever, wheeze, cough, shortness of breath) or
used an incomparable measure (for example, oxygen saturation <
96% (Mazumder 2009) versus oxygen saturation < 90% (Kabir
2009)).
D I S C U S S I O N
Summary of main results
Four included studies did not find any difference between antibi-
otics and placebo for their primary outcomes of length of illness
(Field 1966) or length of hospital stay (Kabir 2009; Kneyber 2008;
Mazumder 2009). One small study of uncertain quality found
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that three weeks of clarithromycin significantly reduced hospital
admission compared to placebo (Tahan 2007). Another study of
uncertain quality found mixed results for the effects of antibi-
otics on wheeze but no difference for other symptom measures
(Mazumder 2009).
Overall completeness and applicability of
evidence
Clinicians may be concerned that if they do not use antibiotics in
a child presenting with a fever and clinical symptoms and signs
of bronchiolitis, they may be putting the child at risk of serious
complications such as pneumonia, septicaemia and death. It has
already been noted that children with this presentation are very
unlikely to have an occult bacteraemia (Greenes 1999). In one
study, paediatricians were less likely to evaluate febrile infants pre-
senting with clinical signs of bronchiolitis for sepsis. In this series
of 219 febrile infants with clinical signs of bronchiolitis, none had
a serious bacterial infection and it was concluded that selective
evaluation for sepsis in this population of febrile infants is appro-
priate (Luginbuhl 2008).
This 2011 updated review includes four new randomised con-
trolled trials (RCTs), all of which investigated the use of macrolide
antibiotics for bronchiolitis. Macrolides are thought to have anti-
inflammatory activities as well as antibiotic activity (Culic 2001)
and sowere thought to have potential in treating bronchiolitis, a vi-
ral condition. Additionally clarithromycin, a macrolide antibiotic,
has been shown to have immune modulatory effects (Ichiyama
2001). One included study (Tahan 2007) hypothesised that clar-
ithromycin would be beneficial for bronchiolitis and found clini-
cal benefit from clarithromycin. However, firm conclusions about
the benefits of clarithromycin for bronchiolitis cannot be drawn
from this study of 21 participants because of the small numbers
and the high risk of potential bias.
Another study examining a macrolide antibiotic, azithromycin (
Kneyber 2008), hypothesised that macrolide antibiotics would
make no difference for bronchiolitis and this was what this study
found. Kneyber 2008 was a larger study and had fewer quality
appraisal concerns. Mazumder 2009 and Kabir 2009 compared
intravenous ampicillin andoral erythromycin for bronchiolitis and
found no significant difference between the two. There was also
no significant difference with control. For Mazumder 2009, the
mixed results of antibiotics on the outcome of wheeze and high
risk of potential bias means this study cannot support the use of
antibiotics in bronchiolitis. No firm conclusions can be drawn
from the empirical evidence contained in this review regarding the
benefits of macrolide antibiotics for bronchiolitis.
Methods to reduce antibiotic use for bronchiolitis have been in-
vestigated. Wilson 2002 found that a clinical pathway reduced
inpatient antibiotic use for bronchiolitis from 27% to 9%.
Childrenwith a serious illness requiring admission to intensive care
and especially those requiring ventilation may have higher rates
of bacterial co-infection possibly justifying the increased use of
antibiotics in this setting (Kneyber 2005; Thorburn 2006). There
have been no RCTs assessing the usefulness of antibiotics for bron-
chiolitis in an intensive care setting. Bloomfield 2004 found that
aside from intensive care admission (2.9%with bacteraemia), chil-
dren with a respiratory syncytial virus (RSV) infection are more
likely to be bacteraemic if they have a nosocomial RSV infection
(6.5% bacteraemia) or cyanotic congenital heart disease (6.6%
bacteraemia). The baseline rate of bacteraemia in children with
RSV bronchiolitis in this study was 0.6%. However, a small study
conducted in a paediatric intensive care unit in the United States
found that otherwise low-risk infants (23 infants) with RSV bron-
chiolitis and respiratory failure had rates of concomitant bacterial
pneumonia at 20% or higher (Levin 2010). Further evaluation
of the risk of secondary bacterial infection following bronchiolitis
would help inform the role of antibiotics in this viral infection,
especially in the context of respiratory failure.
Quality of the evidence
Three small RCTs have examined antibiotics versus placebo with
only 72 participants in antibiotic arms and 72 participants in
placebo arms. The two studies (Field 1966; Kneyber 2008) de-
scribing adequate randomisation conducted in high-income coun-
tries did not find any difference between antibiotic and placebo
arms. The study which found clarithromycin more likely to re-
duce hospital admission than placebo did not adequately describe
randomisation nor allocation concealment and 30% of those ran-
domised were excluded owing to co-administration of corticos-
teroids (Tahan 2007). The inconsistency of results seems most
likely to be owing to the differences in methodological quality.
The study by Tahan 2007 was the only one to use clarithromycin
and the only study to use antibiotics for three weeks. Three stud-
ies have been conducted in low-income countries (Kabir 2009;
Mazumder 2009; Tahan 2007). Both Mazumder 2009 and Kabir
2009 were studies which were at high risk of potential bias. The
included study of highest quality in this review (Kneyber 2008)
is underpowered to make strong conclusions about the worth of
antibiotics for bronchiolitis.
Potential biases in the review process
This 2011 updated review is stronger owing to the inclusion of
four new RCTs and makes a substantial contribution, especially
with regards to the role of macrolides in bronchiolitis. No new
unpublisheddata have been included.However, the review authors
have no reason to suspect that the search strategy has biased the
review results. Raw data could not be obtained from one study
conducted 40 years ago (Field 1966), nor from Tahan 2007,
Mazumder 2009 or Kabir 2009, which is a weakness of this review.
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Some RCT authors did provide raw data for this review (Kneyber
2008).
Agreements and disagreements with other
studies or reviews
Excluded studies comparing antibiotics to placebo in participants
with bronchiolitis did not find any significant difference (Friis
1984).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, this review found conflicting results. However, the two
higher quality but small studies do not support the use of antibi-
otics for bronchiolitis. One small study with a higher risk of po-
tential bias supported the use of macrolide antibiotics, while two
larger studies with higher risk of potential bias did not support the
use of antibiotics, including macrolide antibiotics, for bronchioli-
tis. Antibiotics may be justified in children with bronchiolitis who
have respiratory failure.
Implications for research
Research to identify a possible small subgroup of patients present-
ing with bronchiolitis-like symptoms who may benefit from an-
tibiotics is justified. These might include those with respiratory
failure, in intensive care, with nosocomially acquired RSV, and
with cyanotic congenital heart disease. Otherwise, research may
be better focused on determining the reasons for clinicians to use
antibiotics so readily for bronchiolitis and therefore their use of
antibiotics for bronchiolitis, as well as ways to reduce anxiety.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Field 1966
Methods Randomised controlled trial
Participants Babies
Interventions Ampicillin
Placebo
Outcomes Length of hospital stay
Symptoms (not specified)
Switch to treatment arm
Death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were blinded but not doctors nor outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis but withdrawal rates were
acceptable
Selective reporting (reporting bias) Low risk
Kabir 2009
Methods Randomised controlled trial
Participants Children under 2 years of age with clinical suspected bronchiolitis
Interventions IV ampicillin (parenteral ampicillin 50 mg/kg/6-hourly + supportive care), oral ery-
thromycin (oral erythromycin 10 mg/kg 6-hourly + supportive care), control
Outcomes Respiratory rate, oxygen saturation, wheeze, fever, length of hospital stay, shortness of
breath
Notes
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Kabir 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Seems unlikely, not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 32 participants dropped out (10%), 17 were referred to
paediatric intensive care and 15 withdrew from the study
or left the recruiting hospitals
Selective reporting (reporting bias) High risk
Kneyber 2008
Methods Double-blinded, placebo-controlled, randomised controlled trial
Participants Hospitalised infants younger than 24 months with clinically-confirmed viral lower res-
piratory tract infection
Interventions Azithromycin 10 mg/kg/day, once daily for 3 days
Outcomes Respiratory rate, accessory muscle use, malaise severity, disease complications, use of
alternative therapies, length of hospital stay, length of intensive care stay, deaths, need
for NG feeding
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate block randomisation
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and doctors
14Antibiotics for bronchiolitis in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kneyber 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk
Other bias Low risk
Mazumder 2009
Methods Randomised controlled trial
Participants Children aged 1 month to 2 years presenting to an outpatients department in a teaching
hospital
Interventions Supportive management, supportive management plus IV ampicillin, supportive man-
agement plus oral erythromycin
Outcomes Breathing difficulty, feeding difficulty, social smile, tachypnoea, hypoxia, wheeze,
rhonchi, crepitation, WBC, Hb, ESR, CRP, X-ray, rate of recovery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Odds and evens
Allocation concealment (selection bias) Unclear risk Not discussed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not specified
Selective reporting (reporting bias) Unclear risk Unsure
Tahan 2007
Methods Double-blind, randomised controlled trial
Participants Infants less than or equal to 7 months with immunologically confirmed RSV infection
admitted to 1 hospital
Interventions Clarithromycin 15 mg/kg/day, once daily for 3 weeks
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Tahan 2007 (Continued)
Outcomes Respiratory rate, wheeze, use of supplemental oxygen, cyanosis, hospital admission,
length of stay
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “... infants were randomized by a single
study nurse...”
“Simple randomisation was used”
Allocation concealment (selection bias) Unclear risk Allocation after enrolment by study nurse
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of patients and investigators
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 patients were randomised, however 9
were later excluded as they received corti-
costeroid therapy
Selective reporting (reporting bias) Unclear risk Unsure if trial was registered
Other bias Unclear risk Unsure if therewere any conflicts of interest
CRP: C reactive protein
ESR: erythrocyte sedimentation rate
Hb: haemoglobin
IV: intravenous
NG: nasogastric
RSV: respiratory syncytial virus
WBC: white blood count
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boogaard 2007 Did not study antibiotics
Friis 1984 The patient selection criteria were fine crepitations or consolidation on chest radiograph which was not consistent
with our inclusion criteria of a purely clinical presentation of bronchiolitis
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D A T A A N D A N A L Y S E S
Comparison 1. Length of symptoms (not specified)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of symptoms 2 123 Mean Difference (IV, Fixed, 95% CI) 0.32 [-1.14, 1.78]
2 Duration of fever (days) 1 71 Mean Difference (IV, Fixed, 95% CI) 0.47 [-0.12, 1.06]
Comparison 2. Death
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths 5 543 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Length of hospital stay
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of hospital stay 3 288 Mean Difference (IV, Random, 95% CI) 0.34 [-0.71, 1.38]
Comparison 4. Use of alternative therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Use of alternative therapy 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Oxygen 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Bronchodilator use 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Corticosteroid use 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Naso-gastric feeding 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Duration of bronchodilator use 1 71 Mean Difference (IV, Fixed, 95% CI) -0.17 [-1.25, 0.91]
3 Days of supplementary oxygen 1 71 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.46, 1.18]
4 Days of tube feeding 1 71 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.98, 1.12]
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Comparison 5. PICU admission
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PICU admission 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.02, 10.03]
Comparison 6. Re-admission
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-admission 1 21 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.29]
Comparison 7. Symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Wheeze 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Day 1 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Day 3 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Day 5 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Day 7 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Shortness of breath 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Day 1 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Day 3 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Day 5 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Day 7 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Oxygen saturation (< 96%) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Day 1 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Day 3 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Day 5 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Not smiling socially 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Day 1 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Day 3 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Day 5 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Feeding difficulties 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Day 1 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Day 3 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Day 5 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Fever 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Day 2 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Day 7 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Length of symptoms (not specified), Outcome 1 Duration of symptoms.
Review: Antibiotics for bronchiolitis in children
Comparison: 1 Length of symptoms (not specified)
Outcome: 1 Duration of symptoms
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Field 1966 28 9.54 (0) 24 9.7 (0) Not estimable
Kneyber 2008 32 4.94 (3.78) 39 4.62 (2.05) 100.0 % 0.32 [ -1.14, 1.78 ]
Total (95% CI) 60 63 100.0 % 0.32 [ -1.14, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours treatment Favours control
Analysis 1.2. Comparison 1 Length of symptoms (not specified), Outcome 2 Duration of fever (days).
Review: Antibiotics for bronchiolitis in children
Comparison: 1 Length of symptoms (not specified)
Outcome: 2 Duration of fever (days)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 1.47 (1.41) 39 1 (1.08) 100.0 % 0.47 [ -0.12, 1.06 ]
Total (95% CI) 32 39 100.0 % 0.47 [ -0.12, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 2.1. Comparison 2 Death, Outcome 1 Deaths.
Review: Antibiotics for bronchiolitis in children
Comparison: 2 Death
Outcome: 1 Deaths
Study or subgroup Antibiotics Placebo / Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Field 1966 0/28 0/24 Not estimable
Kabir 2009 0/198 0/97 Not estimable
Kneyber 2008 0/32 0/39 Not estimable
Mazumder 2009 0/61 0/43 Not estimable
Tahan 2007 0/12 0/9 Not estimable
Total (95% CI) 331 212 Not estimable
Total events: 0 (Antibiotics), 0 (Placebo / Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.1. Comparison 3 Length of hospital stay, Outcome 1 Length of hospital stay.
Review: Antibiotics for bronchiolitis in children
Comparison: 3 Length of hospital stay
Outcome: 1 Length of hospital stay
Study or subgroup
Antibiotics
(macrolides) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Random,95% CI IV,Random,95% CI
Kabir 2009 99 4.44 (1.93) 97 3.67 (1.45) 60.4 % 0.77 [ 0.29, 1.25 ]
Kneyber 2008 32 5.5 (2.55) 39 5.82 (2) 39.6 % -0.32 [ -1.40, 0.76 ]
Tahan 2007 12 2.13 (0) 9 3.67 (0) Not estimable
Total (95% CI) 143 145 100.0 % 0.34 [ -0.71, 1.38 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 3.25, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 4.1. Comparison 4 Use of alternative therapy, Outcome 1 Use of alternative therapy.
Review: Antibiotics for bronchiolitis in children
Comparison: 4 Use of alternative therapy
Outcome: 1 Use of alternative therapy
Study or subgroup Antibiotics Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxygen
Kneyber 2008 20/32 31/39 0.43 [ 0.15, 1.24 ]
2 Bronchodilator use
Kneyber 2008 17/32 23/39 0.79 [ 0.31, 2.02 ]
3 Corticosteroid use
Kneyber 2008 1/32 7/39 0.15 [ 0.02, 1.27 ]
4 Naso-gastric feeding
Kneyber 2008 16/32 16/39 1.44 [ 0.56, 3.69 ]
0.01 0.1 1 10 100
Favours Antibiotics Favours Placebo
Analysis 4.2. Comparison 4 Use of alternative therapy, Outcome 2 Duration of bronchodilator use.
Review: Antibiotics for bronchiolitis in children
Comparison: 4 Use of alternative therapy
Outcome: 2 Duration of bronchodilator use
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 2.79 (2.49) 39 2.96 (2.06) 100.0 % -0.17 [ -1.25, 0.91 ]
Total (95% CI) 32 39 100.0 % -0.17 [ -1.25, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 4.3. Comparison 4 Use of alternative therapy, Outcome 3 Days of supplementary oxygen.
Review: Antibiotics for bronchiolitis in children
Comparison: 4 Use of alternative therapy
Outcome: 3 Days of supplementary oxygen
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 3.75 (1.74) 39 3.39 (1.78) 100.0 % 0.36 [ -0.46, 1.18 ]
Total (95% CI) 32 39 100.0 % 0.36 [ -0.46, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 4.4. Comparison 4 Use of alternative therapy, Outcome 4 Days of tube feeding.
Review: Antibiotics for bronchiolitis in children
Comparison: 4 Use of alternative therapy
Outcome: 4 Days of tube feeding
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Fixed,95% CI IV,Fixed,95% CI
Kneyber 2008 32 1.9 (2.13) 39 1.83 (2.36) 100.0 % 0.07 [ -0.98, 1.12 ]
Total (95% CI) 32 39 100.0 % 0.07 [ -0.98, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 5.1. Comparison 5 PICU admission, Outcome 1 PICU admission.
Review: Antibiotics for bronchiolitis in children
Comparison: 5 PICU admission
Outcome: 1 PICU admission
Study or subgroup Antibiotic group Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kneyber 2008 0/32 1/39 100.0 % 0.39 [ 0.02, 10.03 ]
Total (95% CI) 32 39 100.0 % 0.39 [ 0.02, 10.03 ]
Total events: 0 (Antibiotic group), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 6.1. Comparison 6 Re-admission, Outcome 1 Re-admission.
Review: Antibiotics for bronchiolitis in children
Comparison: 6 Re-admission
Outcome: 1 Re-admission
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tahan 2007 1/12 4/9 100.0 % 0.11 [ 0.01, 1.29 ]
Total (95% CI) 12 9 100.0 % 0.11 [ 0.01, 1.29 ]
Total events: 1 (Antibiotics), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 7.1. Comparison 7 Symptoms, Outcome 1 Wheeze.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 1 Wheeze
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 61/61 43/43 Not estimable
2 Day 3
Mazumder 2009 18/61 26/43 0.27 [ 0.12, 0.62 ]
3 Day 5
Mazumder 2009 13/61 2/43 5.55 [ 1.18, 26.05 ]
4 Day 7
Kabir 2009 17/198 4/97 2.18 [ 0.71, 6.68 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 7.2. Comparison 7 Symptoms, Outcome 2 Shortness of breath.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 2 Shortness of breath
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 61/61 43/43 Not estimable
2 Day 3
Mazumder 2009 34/61 27/43 0.75 [ 0.34, 1.66 ]
3 Day 5
Mazumder 2009 16/61 15/43 0.66 [ 0.28, 1.55 ]
4 Day 7
Kabir 2009 17/198 2/97 4.46 [ 1.01, 19.72 ]
0.01 0.1 1 10 100
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Analysis 7.3. Comparison 7 Symptoms, Outcome 3 Oxygen saturation (< 96%).
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 3 Oxygen saturation (< 96%)
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 33/61 23/43 1.02 [ 0.47, 2.24 ]
2 Day 3
Mazumder 2009 15/61 5/43 2.48 [ 0.83, 7.44 ]
3 Day 5
Mazumder 2009 5/61 2/43 1.83 [ 0.34, 9.91 ]
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 7.4. Comparison 7 Symptoms, Outcome 4 Not smiling socially.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 4 Not smiling socially
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 40/61 30/43 0.83 [ 0.36, 1.91 ]
2 Day 3
Mazumder 2009 6/61 5/43 0.83 [ 0.24, 2.91 ]
3 Day 5
Mazumder 2009 0/61 0/43 Not estimable
0.01 0.1 1 10 100
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Analysis 7.5. Comparison 7 Symptoms, Outcome 5 Feeding difficulties.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 5 Feeding difficulties
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 1
Mazumder 2009 25/61 25/43 0.50 [ 0.23, 1.10 ]
2 Day 3
Mazumder 2009 6/61 5/43 0.83 [ 0.24, 2.91 ]
3 Day 5
Mazumder 2009 0/61 0/43 Not estimable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 7.6. Comparison 7 Symptoms, Outcome 6 Fever.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 6 Fever
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 2
Kabir 2009 11/198 4/97 1.37 [ 0.42, 4.41 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 7.7. Comparison 7 Symptoms, Outcome 7 Cough.
Review: Antibiotics for bronchiolitis in children
Comparison: 7 Symptoms
Outcome: 7 Cough
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 7
Kabir 2009 19/198 3/97 3.33 [ 0.96, 11.53 ]
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Kneyber: azithromycin versus placebo for bronchiolitis
Variable Azithromycin (n = 32) Placebo
(n = 39)
Outcome Significance level
Days of symptoms 4.94 (SD 3.78) 4.62 (SD 2.05) Mean difference 0.32 (95%
CI -1.14 to 1.78)
P = 0.65
Days in hospital 5.5 (SD 2.54) 5.82 (SD 1.98) Mean difference -0.32
(95% CI -1.40 to 0.76)
P = 0.56
Duration of fever (days) 1.47 (SD 1.41) 1.00 (SD 1.08) Mean difference 0.47 (95%
CI -0.12 to 1.06)
P = 0.12
Duration of
bronchodilator use
2.79 (SD 2.49) 2.96 (SD 2.06) Mean difference -0.17
(95% CI -1.25 to 0.91)
P = 0.81
Bronchodilator use 17 23 Odds ratio 0.79 (95% CI 0.
31 to 2.02)
P = 0.62
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Table 1. Kneyber: azithromycin versus placebo for bronchiolitis (Continued)
Supplementary oxygen 20 (62.5%) 31 (79.49%) Odds ratio 0.43 (95% CI 0.
15 to 1.24)
P = 0.11
Days of extra oxygen 3.75 (SD 1.74) 3.39 (SD 1.78) Mean difference 0.36 (95%
CI -0.46 to 1.18)
P = 0.48
PICU admission 0 (0%) 1 (2.56%) Odds ratio 0.39 (95% CI 0.
02 to 10.03)
P = 1.00
Tube feeding 16 (50.00%) 16 (41.03%) Odds ratio 1.44 (95% CI 0.
56 to 3.69)
P = 0.45
Days of tube feeding 1.90 (SD 2.13) 1.83 (SD 2.36) Mean difference 0.07 (95%
CI -0.98 to 1.12)
P = 0.90
PICU: paediatric intensive care unit
SD: standard deviation
CI: confidence interval
Table 2. Mazumder: IV ampicillin versus oral erythromycin versus control
Vari-
able
Day 1 Out-
come
Day 3 Out-
come
Day 5 Out-
come
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi
2 test (P
value)
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi
2 test (P
value)
IV
ampi-
cillin
Oral
ery-
thromycin
Control Chi2
test
(P
value)
Wheeze 29/29
(100%)
32/32
(100%)
43/43
(100%)
N/A 16/29
(55%)
2/32
(6%)
26/43
(60%)
24.
82 (P <
0.001)
6/29
(21%)
7/32
(22%)
2/43
(5%)
5.
69 (P =
0.058)
Short-
ness of
breath
29/29
(100%)
32/32
(100%)
43/43
(100%)
N/A 18/29
(62%)
16/32
(50%)
27/43
(63%)
1.97 (P
= 0.37)
8/29
(28%)
8/32
(25%)
15/43
(35%)
0.95 (P
= 0.62)
Oxygen
satura-
tion (<
96%)
18/29
(62%)
15/32
(47%)
23/43
(53%)
1.42 (P
= 0.49)
8/29
(28%)
7/32
(22%)
5/43
(12%)
3.05 (P
= 0.22)
2/29
(7%)
3/32
(9%)
2/43
(5%)
0.65 (P
= 0.72)
Not
smiling
socially
19/29
(66%)
21/32
(66%)
30/43
(70%)
0.20 (P
= 0.90)
3/29
(10%)
3/32
(9%)
5/43
(12%)
0.10 (P
= 0.95)
0/29
(0%)
0/32
(0%)
0/43
(0%)
N/A
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Table 2. Mazumder: IV ampicillin versus oral erythromycin versus control (Continued)
Feed-
ing dif-
ficulty
12/29
(41%)
13/32
(41%)
25/43
(58%)
2.98 (P
= 0.23)
3/29
(10%)
3/32
(9%)
5/43
(12%)
0.10 (P
= 0.95)
0/29
(0%)
0/32
(0%)
0/43
(0%)
N/A
IV: intravenous
Table 3. Kabir: IV ampicillin versus oral erythromycin versus control
Variable Intervention Outcome
IV ampicillin Oral erythromycin Control Chi2 test (P value)
Day 2
Oxygen sats (< 90%) 2/99 (2%) 6/99 (6%) 6/97 (6%) 2.45 (P = 0.29)
Fever 5/99 (5%) 6/99 (6%) 4/97 (4%) 0.38 (P = 0.83)
Day 7
Wheeze 8/99 (8%) 9/99 (9%) 4/97 (4%) 2.04 (P = 0.36)
Shortness of breath 8/99 (8%) 9/99 (9%) 2/97 (2%) 4.68 (P = 0.10)
Cough 10/99 (10%) 9/99 (9%) 3/97 (3%) 4.06 (P = 0.13)
IV: intravenous
PICU: paediatric intensive care unit
SD: standard deviation
CI: confidence interval
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A P P E N D I C E S
Appendix 1. Embase.com search strategy
#36 #24 AND #35
#35 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #33 OR #34
#34 #31 AND #32
#33 placebo*
#32 blind* OR mask*
#31 single* OR doubl* OR trebl* OR tripl*
#30 clinical AND trial*
#29 ’double blind’ OR ’single blind’
#28 ’placebo’/exp
#27 ’clinical trial’/exp
#26 random*
#25 ’randomized controlled trial’/exp
#24 #23 AND [embase]/lim
#23 #19 AND #22
#22 #20 OR #21
#21 child* OR infant* OR pediatric* OR pediatric*
#20 ’child’/exp
#19 #5 AND #18
#18 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#17 tetracycline* OR doxycycline OR methacycline OR minocycline OR amikacin OR gentamicin OR neomycin OR netilmicin OR
clindamycin OR lincomycin OR chloramphenicol OR amantadine OR cotrimoxazole OR trimethoprim
#16 ’tetracycline derivative’/exp
#15 fluoroquinolone* OR ciprofloxacin OR enoxacin OR norfloxacin OR ofloxacin OR pefloxacin OR fleroxacin OR levofloxacin
OR moxifloxacin
#14 ’quinolone derivative’/exp
#13 penicillin* OR amoxicillin OR amoxycillin OR ampicillin OR benzylpenicillin OR cloxacillin OR dicloxacillin OR flucloxacillin
OR piperacillin OR ticarcillin OR sulbactam
#12 ’penicillin derivative’/exp
#11 cephalosporin* OR cephalexin OR cephaclor OR cefaclor OR cefepime OR cefotaxime OR cephamycin* OR cefotetan OR
cefoxitin OR cefmetazole OR cefpirome OR cefpodoxime OR ceftazidime OR ceftriaxone OR cephamandole OR cephazolin
#10 ’cephalosporin derivative’/exp
#9 macrolide* OR azithromycin OR clarithromycin OR erythromycin OR roxithromycin OR spiramycin
#8 ’macrolide’/exp
#7 antibiotic*
#6 ’antibiotic agent’/exp
#5 #1 OR #2 OR #3 OR #4
#4 ’respiratory syncytial virus’ OR ’respiratory syncytial viruses’ OR ’respiratory syncytial virus infection’ OR ’respiratory syncytial virus
infections’ OR rsv*
#3 ’respiratory syncytial pneumovirus’/exp
#2 bronchiolit*
#1 ’bronchiolitis’/exp
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Appendix 2. Current Contents search strategy
# 11 #10 AND #9 AND #8 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 10 #7 OR #6 OR #5 OR #4 OR #3 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 9 #2 OR #1 Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 8 Topic=(Child* or infant* or pediatric or paediatric) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 7 Topic=(tetracycline* or doxycycline or methacycline or minocycline or amikacin or gentamicin or neomycin or netilmicin or
clindamycin or lincomycin or chloramphenicol or amantadine or cotrimoxazole or trimethoprim) Databases=ABES, SBS, CM, LS,
PCES, ECT, AH, EC, BC
# 6 Topic=(fluoroquinolone* or ciprofloxacin or enoxacin or norfloxacin or ofloxacin or pefloxacin or fleroxacin or levofloxacin or
moxifloxacin) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 5 Topic=(penicillin* or amoxicillin or amoxycillin or ampicillin or benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or
piperacillin or ticarcillin or sulbactam)Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 4 Topic=(cephalosporin* or cephalexin or cephaclor or cefaclor or cefepime or cefotaxime or cephamycin* or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftriaxone or cephamandole or cephazolin) Databases=ABES, SBS, CM,
LS, PCES, ECT, AH, EC, BC
# 3 Topic=(macrolide* or azithromycin or clarithromycin or erythromycin or roxithromycin or spiramycin) Databases=ABES, SBS,
CM, LS, PCES, ECT, AH, EC, BC
# 2 Topic=(Respiratory syncytial pneumovirus or Respiratory Syncytial Virus or Respiratory Syncytial Viruses or Respiratory Syncytial
Virus Infection or Respiratory Syncytial Virus Infections or RSV*) Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
# 1 Topic=(Bronchiolit*)Databases=ABES, SBS, CM, LS, PCES, ECT, AH, EC, BC
WH A T ’ S N E W
Last assessed as up-to-date: 9 December 2010.
Date Event Description
16 June 2011 Amended Review First Published date amended.
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 1, 2007
Date Event Description
10 December 2010 New citation required and conclusions have changed A new review author joined the team to update the
review. The conclusions are stronger as they are based
on more trials and address the question of macrolide
antibiotics for bronchiolitis
10 December 2010 New search has been performed We updated the searches and included four new trials
(Kabir 2009; Kneyber 2008; Mazumder 2009; Tahan
2007).
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(Continued)
1 August 2008 Amended Converted to new review format.
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GS co-wrote the protocol; reviewed the search result; performed quality appraisal; extracted data and drafted the final version.
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CDM gave advice on performing the systematic review; performed quality appraisal; extracted data and helped write the final version.
LE conducted the literature search and approved the final version.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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Internal sources
• University of Queensland, Australia.
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External sources
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Ampicillin [therapeutic use]; Anti-Bacterial Agents [∗therapeutic use]; Bronchiolitis [∗drug therapy]; Clarithromycin [therapeutic use];
Erythromycin [therapeutic use]; Length of Stay; Randomized Controlled Trials as Topic
MeSH check words
Humans; Infant
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